Taking stock of the drug industry, from the lab to the medicine chest

August 28, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Opinion: Medicare's new transitional coverage of emerging technologies program doesn't go far enough TCET is built on the existing CED chassis and can be deployed only through Medicare's national coverage authority, limiting its impact. By Peter J. Neumann, Elliott Crummer, Anna Kaltenboeck, and Sean R. Tunis Eli Lilly's lauded discount of its obesity drug Zepbound comes with caveats A deeper look at the announcement suggests the new offering may not expand access as much as the company indicates. By Elaine Chen STAT+ | Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial The compay said the lowest dose of its pill reduced psychosis but higher doses of the drug also tested were ineffective. By Adam Feuerstein STAT+ | UnitedHealth pledged a hands-off approach after buying a Connecticut medical group. Then it upended how doctors practice Health Care's Colossus: The human cost of a corporate strategy that leverages physicians to maximize profits By Lizzy Lawrence, Casey Ross, Bob Herman, and Tara Bannow

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser